{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:18:07Z","timestamp":1783178287716,"version":"3.54.6"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014761","name":"Hope Center for Neurological Disorders, Washington University in St. Louis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-16-1-0286"],"award-info":[{"award-number":["W81XWH-16-1-0286"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P30-AR074992"],"award-info":[{"award-number":["P30-AR074992"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["F30CA254215"],"award-info":[{"award-number":["F30CA254215"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR220013"],"award-info":[{"award-number":["RR220013"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["R01CA248526"],"award-info":[{"award-number":["R01CA248526"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["R01CA237263"],"award-info":[{"award-number":["R01CA237263"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018645","name":"Musculoskeletal Research Center, Washington University in St. Louis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007268","name":"Washington University in St. Louis","doi-asserted-by":"publisher","award":["NCI S10 OD02742"],"award-info":[{"award-number":["NCI S10 OD02742"]}],"id":[{"id":"10.13039\/100007268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54CA199092"],"award-info":[{"award-number":["U54CA199092"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA100730"],"award-info":[{"award-number":["P01 CA100730"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA216840"],"award-info":[{"award-number":["R01 CA216840"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011912","name":"Washington University in St Louis School of Medicine","doi-asserted-by":"publisher","award":["T32CA009547"],"award-info":[{"award-number":["T32CA009547"]}],"id":[{"id":"10.13039\/100011912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jbo.2026.100765","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:45:56Z","timestamp":1777131956000},"page":"100765","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CDK4\/6 inhibitor ribociclib and doxorubicin combination treatment inhibits breast cancer bone metastasis and enhances T-cell targeted therapy"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0351-2928","authenticated-orcid":false,"given":"Xinming","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha N.","family":"Shajahan-Haq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahta","family":"Mardani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleyman","family":"Noordeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaylee","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin A.","family":"Kwakwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory C.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Cybulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Bakewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vindigni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Veis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Achilefu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Lanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine N.","family":"Weilbaecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7015","key":"10.1016\/j.jbo.2026.100765_b0005","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature03097","article-title":"Cell-cycle checkpoints and cancer","volume":"432","author":"Kastan","year":"2004","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jbo.2026.100765_b0010","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0092-8674(95)90385-2","article-title":"The retinoblastoma protein and cell cycle control","volume":"81","author":"Weinberg","year":"1995","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jbo.2026.100765_b0015","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1530\/ERC-18-0317","article-title":"Overcoming CDK4\/6 inhibitor resistance in ER-positive breast cancer","volume":"26","author":"Portman","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.jbo.2026.100765_b0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2018.06.008","article-title":"CDK4\/6 inhibitors in breast cancer therapy: current practice and future opportunities","volume":"191","author":"Lynce","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.jbo.2026.100765_b0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ccell.2020.02.007","article-title":"Chemotherapy and CDK4\/6 Inhibition in Cancer Treatment: timing is everything","volume":"37","author":"Fassl","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbo.2026.100765_b0030","doi-asserted-by":"crossref","unstructured":"E. Boopathi, R. Birbe, S.A. Shoyele, R.B. Den, C. Thangavel, Bone Health Management in the Continuum of Prostate Cancer Disease, Cancers (Basel) 14(17) (2022).","DOI":"10.3390\/cancers14174305"},{"key":"10.1016\/j.jbo.2026.100765_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108280","article-title":"Therapeutics targeting the metastatic breast cancer bone microenvironment","volume":"239","author":"Ihle","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.jbo.2026.100765_b0040","doi-asserted-by":"crossref","DOI":"10.3390\/cells11081309","article-title":"Translational strategies to Target Metastatic Bone Disease","volume":"11","author":"Pagnotti","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jbo.2026.100765_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2023.100505","article-title":"Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms","volume":"43","author":"Joseph","year":"2023","journal-title":"J Bone Oncol"},{"issue":"2","key":"10.1016\/j.jbo.2026.100765_b0050","doi-asserted-by":"crossref","first-page":"150","DOI":"10.23736\/S1824-4785.19.03193-5","article-title":"Response assessment of bone metastatic disease: seeing the forest for the trees RECIST, PERCIST, iRECIST, and PCWG-2","volume":"63","author":"Castello","year":"2019","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"issue":"19","key":"10.1016\/j.jbo.2026.100765_b0055","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1080\/15384101.2016.1204854","article-title":"Fatal attraction: TICs and MDSCs","volume":"15","author":"Welte","year":"2016","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jbo.2026.100765_b0060","doi-asserted-by":"crossref","unstructured":"X. Hao, Y. Shen, N. Chen, W. Zhang, E. Valverde, L. Wu, H.L. Chan, Z. Xu, L. Yu, Y. Gao, I. Bado, L.N. Michie, C.H. Rivas, L.B. Dominguez, S. Aguirre, B.C. Pingel, Y.H. Wu, F. Liu, Y. Ding, D.G. Edwards, J. Liu, A. Alexander, N.T. Ueno, P.R. Hsueh, C.Y. Tu, L.C. Liu, S.H. Chen, M.C. Hung, B. Lim, X.H. Zhang, Osteoprogenitor-GMP crosstalk underpins solid tumor-induced systemic immunosuppression and persists after tumor removal, Cell Stem Cell 30(5) (2023) 648-664 e8.","DOI":"10.1016\/j.stem.2023.04.005"},{"issue":"1","key":"10.1016\/j.jbo.2026.100765_b0065","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41523-024-00625-7","article-title":"Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy","volume":"10","author":"Pascual","year":"2024","journal-title":"npj Breast Cancer"},{"issue":"2","key":"10.1016\/j.jbo.2026.100765_b0070","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.jbo.2026.100765_b0075","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12935-024-03351-z","article-title":"CDK4\/6 inhibition enhances T-cell immunotherapy on hepatocellular carcinoma cells by rejuvenating immunogenicity","volume":"24","author":"Cai","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.jbo.2026.100765_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104010","article-title":"Immune effects of CDK4\/6 inhibitors in patients with HR(+)\/HER2(-) metastatic breast cancer: Relief from immunosuppression is associated with clinical response","volume":"79","author":"Scirocchi","year":"2022","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.jbo.2026.100765_b0085","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1078-0432.CCR-19-1425","article-title":"Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, phase II Neoadjuvant Study in HR(+)\/HER2(-) Breast Cancer","volume":"26","author":"Hurvitz","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.jbo.2026.100765_b0090","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1158\/0008-5472.CAN-04-1844","article-title":"CXCR4 regulates growth of both primary and metastatic breast cancer","volume":"64","author":"Smith","year":"2004","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.jbo.2026.100765_b0095","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1158\/0008-5472.CAN-15-2663","article-title":"Antagonizing Integrin beta3 increases Immunosuppression in Cancer","volume":"76","author":"Su","year":"2016","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.jbo.2026.100765_b0100","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145296","article-title":"Breast cancer-derived GM-CSF regulates arginase 1 in myeloid cells to promote an immunosuppressive microenvironment","volume":"131","author":"Su","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.jbo.2026.100765_b0105","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1172\/JCI38576","article-title":"The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling","volume":"122","author":"Su","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"15","key":"10.1016\/j.jbo.2026.100765_b0110","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","article-title":"SynergyFinder: a web application for analyzing drug combination dose-response matrix data","volume":"33","author":"Ianevski","year":"2017","journal-title":"Bioinformatics"},{"issue":"6","key":"10.1016\/j.jbo.2026.100765_b0115","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.jbo.2026.100765_b0120","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/BF01213553","article-title":"Alterations of the p53, Rb and MDM2 genes in osteosarcoma","volume":"122","author":"Miller","year":"1996","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.jbo.2026.100765_b0125","first-page":"3042","article-title":"Mutation spectrum of the retinoblastoma gene in osteosarcomas","volume":"54","author":"Wadayama","year":"1994","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.jbo.2026.100765_b0130","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ccell.2021.03.010","article-title":"Targeting cell-cycle machinery in cancer","volume":"39","author":"Suski","year":"2021","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.jbo.2026.100765_b0135","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","article-title":"Mechanisms of Sensitivity and Resistance to CDK4\/6 Inhibition","volume":"37","author":"Alvarez-Fernandez","year":"2020","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.jbo.2026.100765_b0140","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2184.2003.00266.x","article-title":"The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer","volume":"36","author":"Vermeulen","year":"2003","journal-title":"Cell Prolif."},{"key":"10.1016\/j.jbo.2026.100765_b0145","article-title":"Mechanisms of CDK4\/6 Inhibitor Resistance in Luminal Breast Cancer","volume":"11","author":"Li","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"16","key":"10.1016\/j.jbo.2026.100765_b0150","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.4161\/cc.21384","article-title":"Metabolic reprogramming of cancer-associated fibroblasts by TGF-beta drives tumor growth: connecting TGF-beta signaling with \u201cWarburg-like\u201d cancer metabolism and L-lactate production","volume":"11","author":"Guido","year":"2012","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.jbo.2026.100765_b0155","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","article-title":"Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jbo.2026.100765_b0160","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.08133","article-title":"TGFbeta-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell anergy in transplant tolerance","volume":"5","author":"Baas","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.jbo.2026.100765_b0165","doi-asserted-by":"crossref","unstructured":"J.C. Jennifer Gao, Mallorie Fiero, Shenghui Tang, Suparna B. Wedam, Melanie E. Royce, Tatiana Michelle Prowell, Elaine Chang, Mirat Shah, Preeti Narayan, Christy Osgood, Nicole Gormley, Tamy Kim, Richard Pazdur, Paul Gustav Kluetz, and Laleh Amiri-Kordestani, Overall survival in patients with HR+\/HER2- advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4\/6 inhibitor plus an aromatase inhibitor: A US Food and Drug Administration pooled analysis, Journal of Clinical Oncology 43 (2025).","DOI":"10.1200\/JCO.2025.43.16_suppl.1055"},{"issue":"6","key":"10.1016\/j.jbo.2026.100765_b0170","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.jbo.2026.100765_b0175","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/CJI.0000000000000281","article-title":"Checkpoint Blockade in Combination with Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma","volume":"42","author":"Wang","year":"2019","journal-title":"J. Immunother."},{"issue":"4","key":"10.1016\/j.jbo.2026.100765_b0180","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/1878-0261.12032","article-title":"Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells","volume":"11","author":"Yang","year":"2017","journal-title":"Mol. Oncol."},{"issue":"14","key":"10.1016\/j.jbo.2026.100765_b0185","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411791","article-title":"CDK4\/6 Inhibitor Resistance in Hormone Receptor-positive Metastatic Breast Cancer: Translational Research, Clinical Trials, and Future Directions","volume":"24","author":"Lee","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.jbo.2026.100765_b0190","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s12032-025-02996-8","article-title":"The landscape of cyclin-dependent kinase 4\/6 inhibitors in solid malignancies: emphasis on immunotherapy combinatorial strategies","volume":"42","author":"Hussein","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.jbo.2026.100765_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.103892","article-title":"Multimodal data integration in early-stage breast cancer","volume":"80","author":"Llinas-Bertran","year":"2025","journal-title":"Breast"},{"issue":"14","key":"10.1016\/j.jbo.2026.100765_b0200","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1158\/0008-5472.CAN-11-0753","article-title":"Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors","volume":"71","author":"Mattarollo","year":"2011","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.jbo.2026.100765_b0205","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/1535-7163.MCT-17-0040","article-title":"CDK4\/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle arrest","volume":"16","author":"Francis","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"7668","key":"10.1016\/j.jbo.2026.100765_b0210","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.jbo.2026.100765_b0215","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2026.100765_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115225","article-title":"Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+\/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials","volume":"217","author":"Hart","year":"2025","journal-title":"Eur. J. Cancer"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137426000278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137426000278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T14:46:18Z","timestamp":1783176378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137426000278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":44,"alternative-id":["S2212137426000278"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2026.100765","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CDK4\/6 inhibitor ribociclib and doxorubicin combination treatment inhibits breast cancer bone metastasis and enhances T-cell targeted therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2026.100765","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100765"}}